Results 1 to 10 of about 87,858 (250)

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors [PDF]

New England Journal of Medicine, 2002
BACKGROUND Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical
George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter Roberts‎, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos J. Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Saša Dimitrijević, Brian J. Druker, Christopher L. Corless, Christopher D.�M. Fletcher, Heikki Joensuu   +20 more
openalex   +2 more sources

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Haematologica, 2016
The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed.
Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Hawk Kim, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny Park, Ji Hyun Kwon, Dong-Wook Kim   +20 more
doaj   +2 more sources

A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome [PDF]

New England Journal of Medicine, 2003
BACKGROUND Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause.
Jan Cools, Daniel J. DeAngelo, Jason Gotlib, Elizabeth H. Stover, Robert D. Legare, Jorge E. Cortés, Jeffrey L. Kutok, Jennifer Clark, Ilene Galinsky, James D. Griffin, Nicholas C.P. Cross, Ayalew Tefferi, James Malone, Rafeul Alam, Stanley L. Schrier, Janet Schmid, Michal G. Rose, Peter Vandenberghe, Gregor Verhoef, Marc Boogaerts, Iwona Włodarska, Hagop M. Kantarjian, Peter Marynen, Steven Coutré, Richard M. Stone, D. Gary Gilliland   +25 more
openalex   +2 more sources

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels [PDF]

Blood, 2003
Corbin and colleagues analyze in their report[1][1] the biochemical and biologic effects of several mutations in the kinase domain of the Bcr-Abl protein identified in patients who developed resistance to imatinib.
Carlo Gambacorti‐Passerini, Rocco Piazza, Maurizio D’Incalci   +2 more
openalex   +3 more sources

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience [PDF]

Vojnosanitetski Pregled, 2021
Background/Aim. The treatment of chronic myeloid leukemia (CML) has changed dramatically with the advent of targeted therapies. This study aimed to assess the efficacy of generic imatinib in CML patients treated in our center. Methods.
Urošević Ivana, Perčić Ivanka, Dragičević-Jojkić Marina, Dokić Marina, El Farra Amir, Savić Aleksandar, Milošević Ivana, Vlaisavljević Nada, Sekulić Borivoj, Balint Bela   +9 more
doaj   +1 more source

Kinase drug discovery 20 years after imatinib: progress and future directions

Nature reviews. Drug discovery, 2021
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or mutations in their genes, cause cancer and other diseases.
Philip Cohen, Darren Cross, P. Jänne
semanticscholar   +1 more source

Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report

Case Reports in Oncology, 2021
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse drug reaction; reported cases are sometimes imatinib mesylate induced.
Hyerin Park, Gil-Soon Choi, Eun Mi Lee
doaj   +1 more source

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Leukemia, 2021
In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death ...
H. Kantarjian, T. Hughes, R. Larson, Dong-Wook Kim, S. Issaragrisil, P. le Coutre, G. Étienne, C. Boquimpani, R. Pasquini, R. Clark, V. Dubruille, I. Flinn, S. Kyrcz‐Krzemień, E. Mędraś, M. Zanichelli, I. Bendit, S. Cacciatore, Ksenia Titorenko, P. Aimone, G. Saglio, A. Hochhaus   +20 more
semanticscholar   +1 more source

Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. [PDF]

PLoS ONE, 2014
Despite the benefits of imatinib for treating gastrointestinal stromal tumors (GIST), the prognosis for high risk GIST and imatinib-resistant (IR) GIST remains poor. The mechanisms of imatinib resistance have not yet been fully clarified.
Hiroyuki Sako, Kazumasa Fukuda, Yoshiro Saikawa, Rieko Nakamura, Tsunehiro Takahashi, Norihito Wada, Hirohumi Kawakubo, Hiroya Takeuchi, Tai Ohmori, Yuko Kitagawa   +9 more
doaj   +1 more source

Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice. [PDF]

PLoS ONE, 2014
Recent studies indicate that tyrosine kinase inhibitors, including imatinib, can reverse hyperglycemia in non-obese diabetic (NOD) mice, a model of type 1 diabetes (T1D). Imatinib inhibits c-Abl, c-Kit, and PDGFRs.
Janet Lau, Qiang Zhou, Susan E Sutton, Ann E Herman, Christian Schmedt, Richard Glynne   +5 more
doaj   +1 more source